These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2667603)

  • 1. Response to vigabatrin in relation to seizure type.
    Michelucci R; Tassinari CA
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):119S-124S. PubMed ID: 2667603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update.
    Browne TR; Mattson RH; Penry JK; Smith DB; Treiman DM; Wilder BJ; Ben-Menachem E; McBride RG; Sherry KM
    Neurology; 1991 Mar; 41(3):363-4. PubMed ID: 2006001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid GABA and seizure control with vigabatrin.
    Riekkinen PJ; Ylinen A; Halonen T; Sivenius J; Pitkanen A
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):87S-94S. PubMed ID: 2757914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin in the treatment of epilepsy in children.
    Livingston JH; Beaumont D; Arzimanoglou A; Aicardi J
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):109S-112S. PubMed ID: 2757901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy.
    Tassinari CA; Michelucci R; Ambrosetto G; Salvi F
    Arch Neurol; 1987 Sep; 44(9):907-10. PubMed ID: 2887152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study.
    Sivenius J; Ylinen A; Murros K; Mumford JP; Riekkinen PJ
    Neurology; 1991 Apr; 41(4):562-5. PubMed ID: 1901397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.
    Mumford JP; Dam M
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):101S-107S. PubMed ID: 2667602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vigabatrin in the treatment of complex partial seizures.
    Knott C; Panayiotopoulos CP
    Seizure; 1992 Sep; 1(3):167-72. PubMed ID: 1344762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vigabatrin as an anticonvulsant against pentylenetetrazol seizures.
    Sayin U; Cengiz S; Altug T
    Pharmacol Res; 1993 Dec; 28(4):325-31. PubMed ID: 8140032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. The Italian Study Group on Vigabatrin.
    Ital J Neurol Sci; 1992 Dec; 13(9):741-7. PubMed ID: 1483856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vigabatrin: a novel therapy for seizure disorders.
    Gidal BE; Privitera MD; Sheth RD; Gilman JT
    Ann Pharmacother; 1999 Dec; 33(12):1277-86. PubMed ID: 10630829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigabatrin in adults with poorly-controlled epilepsy and learning disabilities.
    Armour DJ; Fidler C; Wright EC; Balarajan S
    Seizure; 1992 Sep; 1(3):157-62. PubMed ID: 1344760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex.
    Friedman D; Bogner M; Parker-Menzer K; Devinsky O
    Epilepsy Behav; 2013 Apr; 27(1):118-20. PubMed ID: 23399947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin.
    Lortie A; Chiron C; Mumford J; Dulac O
    Neurology; 1993 Nov; 43(11 Suppl 5):S24-7. PubMed ID: 8232984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vigabatrin for startle-disease with altered cerebrospinal-fluid free gamma-aminobutyric acid.
    Stephenson JB
    Lancet; 1992 Aug; 340(8816):430-1. PubMed ID: 1353584
    [No Abstract]   [Full Text] [Related]  

  • 16. Vigabatrin: rational treatment for chronic epilepsy.
    Ring HA; Heller AJ; Farr IN; Reynolds EH
    J Neurol Neurosurg Psychiatry; 1990 Dec; 53(12):1051-5. PubMed ID: 2292696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of the effectiveness and safety of vigabatrin].
    Jedrzejczak J; Owczarek K
    Neurol Neurochir Pol; 2000; 34 Suppl 1():177-85. PubMed ID: 10768157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
    Grant SM; Heel RC
    Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy.
    Remy C; Beaumont D
    Br J Clin Pharmacol; 1989; 27 Suppl 1(Suppl 1):125S-129S. PubMed ID: 2757903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study.
    Tartara A; Manni R; Galimberti CA; Hardenberg J; Orwin J; Perucca E
    Epilepsia; 1986; 27(6):717-23. PubMed ID: 3536469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.